Loading
SRD5A3 (Polyprenal reductase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Plays a key role in early steps of protein N-linked glycosylation by being involved in the conversion of polyprenol into dolichol. Acts as a polyprenal reductase that mediates the reduction of polyprenal into dolichal in a NADP-dependent mechanism. Dolichols are required for the synthesis of dolichol-linked monosaccharides and the oligosaccharide precursor used for N-glycosylation. Also able to convert testosterone (T) into 5-alpha-dihydrotestosterone (DHT). Location: Endoplasmic reticulum membrane (UniProt). Locus 4q12 (HGNC).
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"SRD5A3" OR ABSTRACT:"SRD5A3" OR TITLE:"steroid 5 alpha-reductase 3" OR ABSTRACT:"steroid 5 alpha-reductase 3" OR TITLE:"Polyprenal reductase" OR ABSTRACT:"Polyprenal reductase" OR TITLE:"FLJ13352" OR ABSTRACT:"FLJ13352" OR TITLE:"SRD5A2L" OR ABSTRACT:"SRD5A2L" OR TITLE:"SRD5A2L1" OR ABSTRACT:"SRD5A2L1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SRD5A3, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/srd5a3.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/srd5a3.json. Licence CC BY-NC 4.0.